Nationwide Voluntary Recall of Artificial Tears Lubricant Eye Drops Due to Potential Contamination

Global Pharma Healthcare, a renowned pharmaceutical company, has taken swift action by initiating a voluntary nationwide recall of its popular product, Artificial Tears Lubricant Eye Drops. This recall comes in response to concerns over potential bacterial contamination, which poses health risks to consumers.

The Food and Drug Administration (FDA) has issued a warning advising against the use of artificial tears lubricant eye drops distributed by EzriCare and Delsam Pharma due to the potential presence of drug-resistant bacteria, specifically Pseudomonas Aeruginosa. Severe eye infections have been reported among individuals who used these over-the-counter products.

Investigations are underway to determine whether contamination occurred during the manufacturing process. Meanwhile, unopened bottles of EzriCare and Delsam Pharma are being tested to ensure product safety. It is important to note that germs can spread in healthcare settings through contaminated hands, equipment, or surfaces.

The use of contaminated artificial tears lubricant eye drops, particularly EzriCare and Delsam, carries potential risks of adverse reactions upon application, such as irritation, inflammation, eye and bloodstream infections, and other undesirable effects. In severe cases, these infections can even lead to blindness. To prioritize patient safety, the Centers for Disease Control and Prevention (CDC) advises individuals who were recommended EzriCare Artificial Tears and Delsam Pharma by their healthcare provider to consult them for an alternative artificial tears product.

Patients who have used EzriCare or Delsam Pharma and are experiencing symptoms of an eye infection should seek immediate medical attention. These symptoms may include yellow, green, or clear discharge from the eye, eye pain or discomfort, redness of the eye or eyelid, increased sensitivity to light, and blurry vision.

Global Pharma Healthcare is dedicated to upholding its commitment to product safety and efficacy. The company is actively investigating and resolving the contamination issue to prevent further incidents. The FDA will closely monitor the situation, working in collaboration with Global Pharma Healthcare to ensure that prompt and necessary actions are taken. The agency remains steadfast in its mission to protect public health by enforcing stringent regulations and standards within the pharmaceutical industry.

Consumers who possess the recalled product are advised to consult with their healthcare provider, as recommended by the FDA, to address any concerns and ensure their continued well-being.

Author: Manny Gonzalez-Brito, DO, LW CMO (LifeWallet Chief Medical Officer).

Sources: 

– Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination | FDA

–  Health Alert Network (HAN) – 00485 | Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial Tears (cdc.gov)

– FDA warns consumers not to purchase or use EzriCare Artificial Tears due to potential contamination | FDA

–  CDC HAN 485

– Pseudomonas aeruginosa Infection | HAI | CDC

Disclaimer:

This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medication, medical condition or treatment.